News

The partnership will build advanced value in Takeda’s operations by consolidating IT platforms across the organization. Under the deal, Wipro will build and maintain a global platform for

Primary liver cancer (hepatocellular carcinoma) is a particularly aggressive cancer resistant to chemotherapy treatments. Hepatocellular carcinoma represents the second leading cause of cancer-related deaths worldwide and it has

Elotuzumab is being co-developed with AbbVie, while BMS is leading the commercialization of the agent. The drug was granted this designation for use in combination with lenalidomide and

Nintedanib is the first targeted treatment for IPF to consistently meet the primary endpoint in two international Phase III trials with identical design. In the two 52 week

The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin – a growing epidemic in the US.

The Breakthrough Therapy designation was granted based on interim efficacy and safety results from an ongoing Phase I/II study of CO-1686. CO-1686 is the company’s novel, oral, targeted

In addition, Endo will assume an existing third party royalty obligation on net sales. The transaction will be financed with Endo’s current cash on hand. Sumavel DosePro is

Fabrus has been successful in generating antibodies against very difficult, therapeutically important cell surface receptors and ion channels resulting in an internal pipeline that includes next generation antibodies

This is the fourth proposal Pfizer has made and it believes that the final proposal provides a clear basis for AstraZeneca to extend the period for making a